J Neuroimmunol. 2011 Jul;236(1-2):81-6. Epub 2011 May 31.
Case Reports in Medicine Volume 2011 (2011), Article ID 393568, 4 pages doi:10.1155/2011/393568 Case Report Neuromyelitis Optica Spectrum Disease with Positive Autoimmune Indices: A Case Report and Review of the Literature M.
The prevalence of neuromyelitis optica in South East Wales.
Published: October 2011 Myasthenia Gravis during the Course of Neuromyelitis Optica Masoud Etemadifar a–d , Seyed-Hossein Abtahi a–c , Alireza Dehghani a,e , Mohammad-Ali Abtahi a,e , Mojtaba Akbari a,f , Nasim Tabrizi a,d , Tannaz Goodarzi g a Medical School, Isfahan University of Medical Sciences, b Isfahan Medical Students Research Committee (IMSRC), c Isfahan Research Committee of Multiple Sclerosis, d Department of Neurology, Medical School, Isfahan University of Medical Sciences, e Ophthalmology Ward, Feiz Hospital, Isfahan University of Medical Sciences, f Department of Epidemiology and Statistics, Isfahan University of Medical Sciences, Isfahan, and g National Institute of Genetic Engineering and Biotechnology, Department of Plant Biotechnology, Canker Group, Tehran, Iran Address of Corresponding Author Case Rep Neurol 2011;3:268-273 (DOI: 10.1159/000334128) ? ? Key Words Neuromyelitis optica Devic’s syndrome Myasthenia gravis Multiple sclerosis Aquaporin-4 Interferon Thymectomy ? ? Abstract Neuromyelitis optica (NMO) is an inflammatory demyelinating disorder of the central nervous system that has been thought to be a severe subtype of multiple sclerosis for a long time. The discovery of aquaporin-4 (AQP4) antibody as a highly specific marker responsible for the pathogenesis of NMO, not only has made a revolutionary pace in establishing a serologic distinction between the two diseases, but it has also classified NMO as an antibody-mediated disorder. Similarly, myasthenia gravis (MG) is a well-known antibody-mediated disorder
Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Costanzi C , Matiello M , Lucchinetti CF , Weinshenker BG , Pittock SJ , Mandrekar J , Thapa P , McKeon A .
Markedly Elevated Soluble Intercellular Adhesion Molecule 1, Soluble Vascular Cell Adhesion Molecule 1 Levels, and Blood-Brain Barrier Breakdown in Neuromyelitis Optica Akiyuki Uzawa, MD; Masahiro Mori, MD, PhD; Saeko Masuda, MD; Satoshi Kuwabara, MD, PhD Arch Neurol. ?2011;68(7):913-917.
The Guthy-Jackson Repository for Neuromyelitis Optica Overview Accelerated Cure Project has formed a partnership with The Guthy-Jackson Charitable Foundation, an organization dedicated to funding basic science research to find answers that will lead to the prevention, clinical treatment programs and a potential cure for Neuromyelitis Optica (NMO) Spectrum Disease. Our two organizations, together with the University of Texas Southwestern (UTSW) are creating a special collection of NMO samples and data to foster scientific collaboration for NMO Spectrum Disease. In this initiative, people with NMO can enroll into the repository at ACP’s collection sites located in leading neurology clinics across the US
Keywords: albumin; antioxidant; bilirubin; neuromyelitis optica; uric acid Background: Oxidative stress plays a central role in neuropathology of multiple sclerosis (MS). The patients with MS have low antioxidant status. Antioxidant therapy may represent an attractive treatment of MS
?Neurol Neurosurg Psychiatry.
Takeshi Matsuoka 1,2 , Satoshi O.
Pathogenic T cell responses against aquaporin 4. Pohl M , Fischer MT , Mader S , Schanda K , Kitic M , Sharma R , Wimmer I , Misu T , Fujihara K , Reindl M , Lassmann H , Bradl M . Source Department of Neuroimmunology, Center for Brain Research, Medical University Vienna, Spitalgasse 4, 1090, Vienna, Austria.
Abstract Aquaporin-4 (AQP4) is a water-selective transporter expressed in astrocytes throughout the central nervous system, as well as in kidney, lung, stomach and skeletal muscle.